Immuneering/$IMRX
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About Immuneering
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Ticker
$IMRX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
54
ISIN
US45254E1073
Website
Immuneering Metrics
BasicAdvanced
$100M
-
-$1.96
-0.23
-
Price and volume
Market cap
$100M
Beta
-0.23
52-week high
$3.80
52-week low
$1.00
Average daily volume
1.5M
Financial strength
Current ratio
7.479
Quick ratio
7.021
Long term debt to equity
8.915
Total debt to equity
9.757
Profitability
EBITDA (TTM)
-63.85
Management effectiveness
Return on assets (TTM)
-57.90%
Return on equity (TTM)
-102.48%
Valuation
Price to book
2.38
Price to tangible book (TTM)
2.86
Price to free cash flow (TTM)
-1.628
Free cash flow yield (TTM)
-61.44%
Free cash flow per share (TTM)
-170.19%
Growth
Earnings per share change (TTM)
5.44%
3-year earnings per share growth (CAGR)
-2.58%
What the Analysts think about Immuneering
Analyst ratings (Buy, Hold, Sell) for Immuneering stock.
Immuneering Financial Performance
Revenues and expenses
Immuneering Earnings Performance
Company profitability
Immuneering News
AllArticlesVideos
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
GlobeNewsWire·5 days ago
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
GlobeNewsWire·6 days ago
Immuneering to Present at the Jefferies Global Healthcare Conference
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Immuneering stock?
Immuneering (IMRX) has a market cap of $100M as of June 20, 2025.
What is the P/E ratio for Immuneering stock?
The price to earnings (P/E) ratio for Immuneering (IMRX) stock is 0 as of June 20, 2025.
Does Immuneering stock pay dividends?
No, Immuneering (IMRX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Immuneering dividend payment date?
Immuneering (IMRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Immuneering?
Immuneering (IMRX) has a beta rating of -0.23. This means that it has an inverse relation to market volatility.
